Immune checkpoint inhibitors have emerged as an effective treatment for several tumor types and their use in clinical practice is expected to further increase in the immediate future. Although these agents are well tolerated, they are associated with a peculiar spectrum of toxicity, which is immune mediated and may potentially affect every organ. However, immune-related adverse events are mostly reversible if promptly diagnosed and adequately treated. Therefore, it is crucial that medical oncologists know how to diagnose and treat immune-related adverse events. This review focuses on the pathogenesis, clinical manifestations and management of immune-related toxicity of anti-CTLA-4 and anti-PD-1 antibodies.
DunnGPBruceATIkedaHOldLJSchreiberRDCancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol.2002;3 (11):991–998.
2.
DunnGPOldLJSchreiberRDThe three Es of cancer immunoediting. Annu Rev Immunol.2004;22 (1):329–360.
3.
ShankaranVIkedaHBruceATIFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature.2001;410 (6832):1107–1111.
4.
SchreiberRDOldLJSmythMJCancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science.2011;331 (6024):1565–1570.
5.
DunnGPOldLJSchreiberRDThe immunobiology of cancer immunosurveillance and immunoediting. Immunity.2004;21 (2):137–148.
6.
VeselyMDKershawMHSchreiberRDSmythMJNatural innate and adaptive immunity to cancer. Annu Rev Immunol.2011;29 (1):235–271.
7.
MellmanICoukosGDranoffGCancer immunotherapy comes of age. Nature.2011;480 (7378):480–489.
8.
HodiFSODaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med.2010;363 (8):711–723.
9.
LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med.2015;373 (1):23–34.
10.
RobertCSchachterJLongGVKEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med.2015;372 (26):2521–2532.
11.
WeberJSDAngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol.2015;16 (4):375–384.
12.
EggermontAMChiarion-SileniVGrobJJProlonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med.2016;375 (19):1845–1855.
13.
ReckMRodríguez-AbreuDRobinsonAGKEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med.2016;375 (19):1823–1833.
14.
BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med.2015;373 (2):123–135.
15.
BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med.2015;373 (17):1627–1639.
16.
RittmeyerABarlesiFWaterkampDOAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet.2017;389 (10066):255–265.
17.
HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet.2016;387 (10027):1540–1550.
18.
MotzerRJEscudierBMcDermottDFCheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med.2015;373 (19):1803–1813.
19.
FerrisRLBlumenscheinGJrFayetteJNivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med.2016;375 (19):1856–1867.
20.
MehraRSeiwertTYMahipalAEfficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): pooled analyses after long-term follow-up in KEYNOTE-012. J Clin Oncol.2016;34(Suppl):abstr. 6012.
21.
RosenbergJEHoffman-CensitsJPowlesTAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet.2016;387 (10031):1909–1920.
22.
AnsellSMLesokhinAMBorrelloIPD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med.2015;372 (4):311–319.
KosterBDde GruijlTDvan den EertweghAJRecent developments and future challenges in immune checkpoint inhibitory cancer treatment. Curr Opin Oncol.2015;27 (6):482–488.
28.
MichotJMBigenwaldCChampiatSImmune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer.2016;54:139–148.
29.
MinkisKGardenBCWuSPulitzerMPLacoutureMEThe risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol.2013;69 (3):e121–e128.
30.
Abdel-RahmanOElHalawaniHFouadMRisk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol.2015;11 (17):2471–2484.
31.
ChengRCooperAKenchJIpilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol.2015;30 (4):657–666.
32.
GentileNMD'SouzaAFujiiLLWuTTMurrayJAAssociation between ipilimumab and celiac disease. Mayo Clin Proc.2013;88 (4):414–417.
33.
RyderMCallahanMPostowMAWolchokJFaginJAEndocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer.2014;21 (2):371–381.
34.
GaudyCClévyCMonestierSAnti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care.2015;38 (11):e182–e183.
35.
BarjaktarevicIZQadirNSuriASantamauroJTStoverDOrganizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest.2013;143 (3):858–861.
36.
BerthodGLazorRLetovanecIPulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol.2012;30 (17):e156–e159.
37.
FordePMRockKWilsonGO'ByrneKJIpilimumab-induced immune-related renal failure–a case report. Anticancer Res.2012;32 (10):4607–4608.
38.
IzzedineHGueutinVGharbiCKidney injuries related to ipilimumab. Invest New Drugs.2014;32 (4):769–773.
39.
BernardoSGMoskalenkoMPanMElevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res.2013;23 (1):47–54.
40.
KleinerDEBermanDPathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci.2012;57 (8):2233–2240.
41.
ThaipisuttikulIChapmanPAvilaEKPeripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother.2015;38 (2):77–79.
42.
LoochtanAINickolichMSHobson-WebbLDMyasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve.2015;52 (2):307–308.
43.
WeberJSYangJCAtkinsMBDisisMLToxicities of immunotherapy for the practitioner. J Clin Oncol.2015;33 (18):2092–2099.
44.
PiccirilloCAShevachEMNaturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol.2004;16 (2):81–88.
45.
TakahashiTTagamiTYamazakiSImmunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med.2000;192 (2):303–310.
46.
ChambersCAKuhnsMSEgenJGAllisonJPCTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol.2001;19 (1):565–594.
47.
MuellerDLJenkinsMKSchwartzRHClonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol.1989;7 (1):445–480.
48.
WaterhousePPenningerJMTimmsELymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science.1995;270 (5238):985–988.
49.
TivolEABorrielloFSchweitzerANLynchWPBluestoneJASharpeAHLoss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity.1995;3 (5):541–547.
50.
LoBZhangKLuWPatients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science.2015;349 (6246):436–440.
51.
LoBFritzJMSuHCUzelGJordanMBLenardoMJCHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood.2016;128 (8):1037–1042.
52.
NurievaRILiuXDongCYin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev.2009;229 (1):88–100.
53.
KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunity. Annu Rev Immunol.2008;26 (1):677–704.
54.
YokosukaTTakamatsuMKobayashi-ImanishiWHashimoto-TaneAAzumaMSaitoTProgrammed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med.2012;209 (6):1201–1217.
55.
JinHTAhmedROkazakiTRole of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol.2011;350:17–37.
56.
FifeBTPaukenKEThe role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci.2011;1217 (1):45–59.
57.
KonishiJYamazakiKAzumaMKinoshitaIDosaka-AkitaHNishimuraMB7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res.2004;10 (15):5094–5100.
58.
NomiTShoMAkahoriTClinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res.2007;13 (7):2151–2157.
59.
OhigashiYShoMYamadaYClinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res.2005;11 (8):2947–2953.
60.
YoungnakPKozonoYKozonoHDifferential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun.2003;307 (3):672–677.
61.
AkbariOStockPSinghAKPD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol.2010;3 (1):81–91.
62.
HuberSHoffmannRMuskensFVoehringerDAlternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood.2010;116 (17):3311–3320.
63.
ButteMJKeirMEPhamduyTBSharpeAHFreemanGJProgrammed death-1 ligand 1 interacts specifically with the B71 costimulatory molecule to inhibit T cell responses. Immunity.2007;27 (1):111–122.
64.
OttPAHodiFSRobertCCTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res.2013;19 (19):5300–5309.
65.
PardollDMThe blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer.2012;12 (4):252–264.
66.
ChenDSIrvingBAHodiFSMolecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res.2012;18 (24):6580–6587.
67.
FifeBTBluestoneJAControl of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev.2008;224 (1):166–182.
68.
ChenLCo-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol.2004;4 (5):336–347.
69.
ZouWChenLInhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol.2008;8 (6):467–477.
70.
Suarez-AlmazorMEKimSTAbdel-WahabNDiabAImmune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol.2017Jan13.
71.
NoackMMiossecPTh17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev.2014;13 (6):668–677.
72.
OkazakiTTanakaYNishioRAutoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med.2003;9 (12):1477–1483.
73.
KanameishiSOtsukaANonomuraYFujisawaAEndoYKabashimaKIdiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol.2016;27 (3):546–547.
74.
KongYCFlynnJCOpportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front Immunol.2014;5:206.
75.
WeberJSKudchadkarRRYuBSafety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol.2013;31 (34):4311–4318.
76.
Abdel-RahmanOHelblingDSchmidtJTreatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors; a systematic review and meta-analysis. Clin Oncol (R Coll Radiol).2016;28 (10):e127–e138.
77.
WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol.2010;11 (2):155–164.
78.
AsciertoPADel VecchioMRobertCOverall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL). Ann Oncol.2016;27 (Suppl 6):1106O.
79.
TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med.2012;366 (26):2443–2454.
80.
BertrandAKostineMBarnetcheTTruchetetMESchaeverbekeTImmune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med.2015;13 (1):211.
81.
WeberJSKählerKCHauschildAManagement of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol.2012;30 (21):2691–2697.
82.
WeberJSDummerRde PrilVLebbéCHodiFSMDX01020 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer.2013;119 (9):1675–1682.
AntoniaSJLópez-MartinJABendellJNivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol.2016;17 (7):883–895.
85.
HammersHPlimackERInfanteJRUpdated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): the CheckMate 016 study. Ann Oncol.2016;27 (suppl 6):1062P.
86.
HellmannMDRizviNAGoldmanJWNivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol.2017;18 (1):31–41.
87.
FecherLAAgarwalaSSHodiFSWeberJSIpilimumab and its toxicities: a multidisciplinary approach. Oncologist.2013;18 (6):733–743.
88.
BoutrosCTarhiniARoutierESafety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol.2016;13 (8):473–486.
89.
ChampiatSLambotteOBarreauEManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol.2016;27 (4):559–574.
90.
O'ConnorAMarplesMMulateroCHamlinJFordACIpilimumab-induced colitis: experience from a tertiary referral center. Therap Adv Gastroenterol.2016;9 (4):457–462.
91.
NaidooJPageDBLiBTToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol.2015;26 (12):2375–2391.
92.
PostowMAManaging immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book.2015;35:76–83.
93.
LacoutureMEWolchokJDYosipovitchGKählerKCBusamKJHauschildAIpilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol.2014;71 (1):161–169.
94.
HodiFSMihmMCSoifferRJBiologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA.2003;100 (8):4712–4717.
95.
PintovaSSidhuHFriedlanderPAHolcombeRFSweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res.2013;23 (6):498–501.
96.
TopalianSLSznolMMcDermottDFSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol.2014;32 (10):1020–1030.
97.
BermanDParkerSMSiegelJBlockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun.2010;10:11.
98.
MakerAVPhanGQAttiaPTumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol.2005;12 (12):1005–1016.
99.
StidhamRWLeeTCHigginsPDSystematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. Aliment Pharmacol Ther.2014;39 (12):1349–1362.
100.
WeberJThompsonJAHamidOA randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res.2009;15 (17):5591–5598.
101.
KimKWRamaiyaNHKrajewskiKMIpilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs.2013;31 (4):1071–1077.
102.
TirumaniSHRamaiyaNHKeraliyaARadiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res.2015;3 (10):1185–1192.
103.
HofmannLForschnerALoquaiCCutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer.2016;60:190–209.
104.
O'DaySJMaioMChiarion-SileniVEfficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol.2010;21 (8):1712–1717.
105.
ChmielKDSuanDLiddleCResolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol.2011;29 (9):e237–e240.
106.
RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med.2011;364 (26):2517–2526.
107.
AhmedTPandeyRShahBBlackJResolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep.2015;2015. pii: bcr2014208102.
108.
EckertASchoefflerADalleSPhanAKiakouamaLThomasLAnti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology.2009;218 (1):69–70.
109.
VogelWVGuislainAKvistborgPSchumacherTNHaanenJBBlankCUIpilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol.2012;30 (2):e7–e10.
110.
NaidooJWangXWooKMPneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol.2017;35 (7):709–717.
111.
NishinoMChambersESChongCRAnti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res.2016;4 (4):289–293.
112.
WanchooRKaramSUppalNNCancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol.2017;45 (2):160–169.
113.
FadelFEl KarouiKKnebelmannBAnti-CTLA4 antibody-induced lupus nephritis. N Engl J Med.2009;361 (2):211–212.
114.
VoskensCJGoldingerSMLoquaiCThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE.2013;8 (1):e53745.
115.
SpainLDiemSLarkinJManagement of toxicities of immune checkpoint inhibitors. Cancer Treat Rev.2016;44:51–60.
116.
TorinoFBarnabeiAParagliolaRMMarchettiPSalvatoriRCorselloSMEndocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol.2013;169 (6):R153–R164.
117.
WeberJSO'DaySUrbaWPhase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol.2008;26 (36):5950–5956.
118.
CorselloSMBarnabeiAMarchettiPDe VecchisLSalvatoriRTorinoFEndocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab.2013;98 (4):1361–1375.
119.
JohnsonDBFriedmanDLBerryESurvivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res.2015;3 (5):464–469.
120.
DillardTYedinakCGAlumkalJFleseriuMAnti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary.2010;13 (1):29–38.
121.
Martin-LiberalJFurnessAJJoshiKPeggsKSQuezadaSALarkinJAnti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother.2015;64 (6):765–767.
122.
RizviNAMazièresJPlanchardDActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol.2015;16 (3):257–265.
123.
GaronEBRizviNAHuiRKEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med.2015;372 (21):2018–2028.
124.
MotzerRJRiniBIMcDermottDFNivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol.2015;33 (13):1430–1437.
125.
Gaudy-MarquesteCMonestierSFranquesJCantaisERichardMAGrobJJA severe case of ipilimumab-induced Guillain-Barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother.2013;36 (1):77–78.
126.
AntounJTitahCCochereauIOcular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol.2016;28 (4):288–294.
127.
PapavasileiouEPrasadSFreitagSKSobrinLLoboAMIpilimumab-induced ocular and orbital inflammation–a case series and review of the literature. Ocul Immunol Inflamm.2016;24 (2):140–146.
128.
Abdel-WahabNShahMSuarez-AlmazorMEAdverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS ONE.2016;11 (7):e0160221.
129.
ZimmerLGoldingerSMHofmannLNeurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer.2016;60:210–225.
130.
RobinsonMRChanCCYangJCCytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother.2004;27 (6):478–479.
131.
Abu SamraKValdes-NavarroMLeeSSwanRFosterCSAnesiSDA case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol.2016;26 (3):e46–e48.
132.
De VelascoGBermasBChoueiriTKAutoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheum (Munch).2016;68 (2):556–557.
133.
WongRKLeeJKHuangJJBilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome. Retin Cases Brief Rep.2012;6 (4):423–426.
134.
VilladolidJAminAImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res.2015;4 (5):560–575.
135.
TorinoFCorselloSMSalvatoriREndocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol.2016;28 (4):278–287.
136.
AlabedYZAghayevASakellisCVan den AbbeeleADPancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT. Clin Nucl Med.2015;40 (11):e528–e529.
137.
KwonEDDrakeCGScherHICA184043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol.2014;15 (7):700–712.
138.
RibasAKeffordRMarshallMAPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol.2013;31 (5):616–622.
139.
WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanoma. N Engl J Med.2013;369 (2):122–133.
140.
PostowMAChesneyJPavlickACNivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med.2015;372 (21):2006–2017.
141.
GreenplateARJohnsonDBRousselMMyelodysplastic syndrome revealed by systems immunology in a melanoma patient undergoing anti-PD-1 therapy. Cancer Immunol Res.2016;4 (6):474–480.
142.
KongBYMicklethwaiteKPSwaminathanSKeffordRFCarlinoMSAutoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res.2016;26 (2):202–204.
143.
InadomiKKumagaiHAritaSBi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: a case report. Medicine (Baltimore).2016;95 (29):e4283.
144.
GordonIOWadeTChinKDicksteinJGajewskiTFImmune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother.2009;58 (8):1351–1353.
145.
AkhtariMWallerEKJayeDLNeutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother.2009;32 (3):322–324.
146.
DelyonJMateusCLambertTHemophilia A induced by ipilimumab. N Engl J Med.2011;365 (18):1747–1748.
147.
KopeckýJTrojanováPKubečekOKopeckýOTreatment possibilities of ipilimumab-induced thrombocytopenia–case study and literature review. Jpn J Clin Oncol.2015;45 (4):381–384.
148.
AhmadSLewisMCorriePIddawelaMIpilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J Oncol Pharm Pract.2012;18 (2):287–292.
149.
QuirkSKShureAKAgrawalDKImmune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res.2015;166 (5):412–424.
150.
AttiaPPhanGQMakerAVAutoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol.2005;23 (25):6043–6053.
151.
BeckKEBlansfieldJATranKQEnterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol.2006;24 (15):2283–2289.
152.
YangJCHughesMKammulaUIpilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother.2007;30 (8):825–830.
153.
DowneySGKlapperJASmithFOPrognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res.2007;13 (22 Pt 1):6681–6688.
154.
ArriolaEWheaterMGaleaIOutcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J Thorac Oncol.2016;11 (9):1511–1521.
155.
HorvatTZAdelNGDangTOImmune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol.2015;33 (28):3193–3198.
156.
Di GiacomoAMGrimaldiAMAsciertoPACorrelation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP). J Clin Oncol.2013;31(Suppl):abstr. 9065.
157.
HuaCBoussemartLMateusCAssociation of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol.2016;152 (1):45–51.
158.
SanlorenzoMVujicIDaudAPembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol.2015;151 (11):1206–1212.
159.
Freeman-KellerMKimYCroninHRichardsAGibneyGWeberJSNivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res.2016;22 (4):886–894.
160.
LoJAFisherDEFlahertyKTPrognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol.2015;1 (9):1340–1341.
161.
GrimaldiAMSimeoneEFestinoLCorrelation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients. J Immunother Cancer.2015;3 (Suppl 2):186.
162.
LeighlNGandhiLHellmannMDPembrolizumab for NSCLC: immune-mediated adverse events and corticosteroid use. J Thorac Oncol.2015;10 (Suppl 2):S233.
163.
TarhiniAImmune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo).2013;2013:857519.
164.
SharmaAThompsonJARepakaAMehnertJMIpilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol.2013;31 (21):e370–e372.
165.
RaviSSpencerKRuisiMIpilimumab administration for advanced melanoma in patients with pre-existing hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer.2014;2 (1):33.
166.
DavarDWilsonMPrucknerCKirkwoodJMPD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep Oncol Med.2015;2015:737389.
167.
SangroBGomez-MartinCde la MataMA clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol.2013;59 (1):81–88.
168.
GardinerDLalezariJLawitzEA randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS ONE.2013;8 (5):e63818.
169.
RaoMValentiniDDodooEZumlaAMaeurerMAnti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis.2017;56:221–228.
170.
JohnsonDBSullivanRJOttPAIpilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol.2016;2 (2):234–240.
171.
MenziesAMJohnsonDBRamanujamSAnti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol.2016Sep29[Epub ahead of print].
